Brii Biosciences Limited focuses on developing therapies for the treatment of infectious and central nervous system diseases in China and the United States. The company develops BRII-179, a recombinant protein-based HBV immunotherapeutic candidate; Elebsiran, an investigational subcutaneously administered HBV-targeting siRNA; and Tobevibart, an investigational subcutaneously administered HBV-neutralizing monoclonal antibody which are in Phase 2 of the development stage for functional cure of HBV for Hepatitis B; and BRII-732 that has completed Phase 1 clinical trial and BRII-753, which is in preclinical stage for the treatment of HIV. It also develops BRII-693 for the treatment of multi-drug resistant/extensive drug resistant (MDR/XDR) gram-negative bacterial infections, which has completed Phase 1; and Epetraborole for oral treatment for patients with chronic NTM lung disease. Brii Biosciences Limited was incorporated in 2017 and is headquartered in Beijing, China.
Metrics to compare | 2137 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship2137PeersSector | |
---|---|---|---|---|
P/E Ratio | −2.7x | −19.4x | −0.5x | |
PEG Ratio | 0.01 | 0.29 | 0.00 | |
Price/Book | 0.5x | 6.7x | 2.6x | |
Price / LTM Sales | 27.3x | 19.2x | 3.3x | |
Upside (Analyst Target) | −47.7% | −1.3% | 43.5% | |
Fair Value Upside | Unlock | −15.6% | 6.9% | Unlock |